| NCT ID | NCT03149705 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hospices Civils de Lyon |
| Condition | Ischemic Stroke |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2016-10-13 |
| Primary Completion | 2026-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2016-10-13 with a primary completion date of 2026-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Ischemic stroke is the first cause of acquired disability of the adult, the second cause of dementia and the third cause of death in the industrialized countries, what constitutes à major public health issue. Stroke is characterized by a cerebral parenchymal lesion due to an ischemic mechanism (85% of the cases) or hemorrhagic mechanism (15%). For a long time, the only approved treatment was the intravenous thrombolysis (rt-PA). Recently, thrombectomy has proven its superiority in this pathology. Cohorts of patients with stroke are rare but can be very valuable by their clinical, laboratory and imaging well documented. They are the source of new hypotheses for research or interventions as well as the quality of care assessment tool. The main objective of this project is to identify new markers: biological and imaging, treatment response and prognosis after ischemic stroke. Secondary objectives of the HIBISCUS-STROKE cohort are to establish a clinical database, completed by biological samples and by imaging data that can be used in the following areas: * Descriptive epidemiology of ischemic stroke and cerebral reperfusion, * Pharmacoepidemiology and treatments observatory: safety, efficacy, indication of treatment in real life, costs * Assessment of the long-term effect of the treatment on the occurrence of disability, stroke recurrence and death, * Quality of life and personal, familial, professional and social consequences of stroke, * Research of new diagnostic and prognostic biomarkers, * Research projects.
Eligibility Criteria
Inclusion Criteria: * Age\> 18 years * Ischemic Stroke confirmed by MRI * Proximal arterial occlusion (ICA or M1) * Eligible for thrombolysis and/or thrombectomy Exclusion Criteria: * Patients residing\> 50 km from the Pierre Wertheimer Hospital (Lyon, France) * Inability to perform the first sample (H0) * Patient with progressive or uncontrolled cancer. * Refusal to participate in the study or to sign the consent * Lack of medical social coverage * Deprivation of civil rights
Contact & Investigator
Frequently Asked Questions
Who can join the NCT03149705 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Ischemic Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03149705 currently recruiting?
Yes, NCT03149705 is actively recruiting participants. Contact the research team at GHE.CICLYON@chu-lyon.fr for enrollment information.
Where is the NCT03149705 trial being conducted?
This trial is being conducted at Bron, France.
Who is sponsoring the NCT03149705 clinical trial?
NCT03149705 is sponsored by Hospices Civils de Lyon. The trial plans to enroll 300 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.